Provided by Tiger Trade Technology Pte. Ltd.

Hillhouse Capital Holdings

4,813.92
-37.7354-0.78%
Number of Gainers:7
Number of Losers:56
Number of Flat:2
PE:- -
High:4,862.74
Open:4,862.74
Low:4,797.34
Close:4,851.65
Volume:317.65M
Turnover:26.97B
Market Cap:8.59T
Float Cap:8.15T

Loading ...

BridgeBio Pharma Price Target Maintained with a $120.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 10

GenScript Unit Legend Biotech to Present Updated Long-Term Carvykti Cartitude-2 Data at IMS Meeting

Reuters
·
Sep 10

Apple's Stock Rises After iPhone Reveal. the Company is Walking a 'tightrope' on Pricing, Say Analysts.

Dow Jones
·
Sep 10

Breakingviews-Apple Eyes Way to Cash in on Maturing iPhone Users

Reuters
·
Sep 10

Prelude Therapeutics IND Cleared for Novel Breast Cancer Drug

TIPRANKS
·
Sep 10

Apple Price Target Cut to $370.00/Share from $380.00 by B of a Securities

Dow Jones
·
Sep 10

The Ternus Era's First Big Bet: Can Duo Deliver Apple's Next "IPhone Moment"?

Bellwether Stocks Movement
·
Sep 10

Buy the Stocks Dip or Foldable iPhone? How to Spend Trump's $5,000 Handout.

Dow Jones
·
Sep 10

Apple's Launch Sparks Two Key Investment Chains: Universal Scientific Industrial Hits Daily Limit While Lingyi Itech Surges, With Electronic ETF (515260) Holding 30% Apple Supply Chain Exposure

Deep News
·
Sep 10

Technoprobe Buoyed by TSMC Earnings

Dow Jones
·
Sep 10

Apple Raises Prices on Existing iPhone Models in India by Up to 41%

MT Newswires Live
·
Sep 10

Apple product luanch inline with expectations, says JPMorgan

TIPRANKS
·
Sep 10

Prelude Therapeutics receives FDA clearance for PRT13722 IND application

TIPRANKS
·
Sep 10

TSMC Posts Record Sales. Why AMD and Other Chip Stocks are Falling

Dow Jones
·
Sep 10

Airbnb, Inc. : Truist Securities Raises Target Price to $161 from $134

THOMSON REUTERS
·
Sep 10

Apple Stock Likely to ‘Outperform,’ Says Gene Munster after Foldable iPhone Reveal

TIPRANKS
·
Sep 10

Prelude Therapeutics Says FDA Clears IND for Prt13722 in Hr+/her2- Breast Cancer

Reuters
·
Sep 10

Prelude Therapeutics Incorporated - Expects to Begin Enrolling Patients in Q4 2026

THOMSON REUTERS
·
Sep 10

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (Ind) Application for Prt13722, Its First-in-Class Oral Kat6a Selective Degrader

THOMSON REUTERS
·
Sep 10

Nkarta to Participate in September Investor Conferences

GlobeNewswire
·
Sep 10